STAT+: Pharmalittle: We’re reading about Dems eyeing Trump MFN deals, fewer drug launches in Europe, and more
… The incoming Democratic chairs of key committees have taken a new step toward investigating the most-favored nation drug pricing agreements between drugmakers and the Trump administration, STAT reports.
Key points
- There has been a 27% drop in new drug releases across European countries over the last 17 months, compared with the same period before President Trump announced the plan, according to new data from market-research firm GlobalData.
- The drug pricing deals are expected to be a top health care oversight priority for Democrats once they take the majority in January.
- remain high and there are fewer new drugs in Europe, The Wall Street Journal says.
The Trump administration last year came up with a plan to combat high drug prices, making European governments pay more, and the result so far is that drug prices in the U.S.
Additional details
- Meanwhile, drug approvals in Europe have held steady over that time period.
- Congratulations on making it this far, and remember there are only a few more days until the weekend arrives.
- Our choice today is butter pecan with a dollop of bourbon honey (for the curious, the honey is procured locally from a family with beehives in their backyard).
- Continue to STAT+ to read the full story….
- While you ponder the possibilities, we invite you to join us for a needed cup of stimulation.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 1 article from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.